Researchers discover an epigenetic lesion in the hippocampus of Alzheimer's

In pink is the location and structure of the brain hippocampus, the region where the epigenetic lesion was found in Alzheimer's patients. Credit: IDIBELL

Alzheimer's disease can reach epidemic range in the coming decades, by the increasing average age of society. There are two key issues for Alzheimer's disease: there is currently no effective treatment and it has been described very few associated genetic changes (mutations) which reduces the number of targets for future therapies.

Alzheimer's disease

Pathologically, Alzheimer 's disease is characterized by the accumulation of protein deposits in the brain of . These deposits are formed by plates of a protein called amyloid-beta and rolled tangles of . The root cause of these lesions in most cases is unknown, but specific alterations in regulating genes expression might be involved.

Today , the prestigious international journal in neurology Hippocampus publishes an article led by Manel Esteller, Director of Epigenetics and Cancer Biology , Institute of Biomedical Research of Bellvitge (IDIBEL ) , ICREA researcher and Professor of Genetics at the University of Barcelona,with the collaboration of the Institute of Neuropathology IDIBELL led by Isidre Ferrer, demonstrating for the first time the existence of an epigenetic lesion in the hippocampus of the brain of patients with Alzheimer.

Switches in the hippocampus

" We first started studying 30,000 molecular switches that turn on and off genes in the hippocampal region in the brains of Alzheimer patients in different stages of disease and compared with that of healthy patients of the same age. We note that dusp22 gene switch off (methylated) as the disease advances" explained Manel Esteller, director of the study.

"But more importantly" continues "was the discovery that this gene regulates tau protein. Perhaps therefore the accumulation of tau protein produced in the brain of patients with Alzheimer results from dusp22 epigenetic inactivation " .

According Esteller " the finding is relevant not only to determine the causes of the disease, but also to test potential treatments in the future to act on these epigenetic molecular switches " .

More information: Sanchez-Mut JV, Aso E, Heyn H, Matsuda T, Bock C, Ferrer I, Esteller M. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus, DOI: 10.1002/hipo.22245, 2014.

Related Stories

Mechanism in Alzheimer's-related memory loss identified

Jan 19, 2014

Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer's patients, according to a study to be published in the journal Nature Neuroscience and po ...

Recommended for you

New technique could benefit Alzheimer's diagnosis

17 hours ago

Swinburne researchers have developed a technique to create a highly sensitive surface for measuring the concentration of a peptide that is a biomarker for early stage Alzheimer's disease.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JVK
not rated yet Jan 21, 2014
This is the first time I've seen a neurodegenerative disease accurately attributed to epigenetic effects instead of to mutations. Loss of olfactory acuity and specificity is one of the predictors of Alzheimer's.

This article appears to links nutrient stress and social stress from my model to a neurodegenerative disease via conserved molecular mechanisms that link the same stressors to many other diseases and disorders. Most of these diseases and disorders are typically associated with mutations when they probably should be examined in the light of how the epigenetic landscape becomes the physical landscape of DNA in the organized genomes of species from microbes to man.

Evolutionary theorists are largely responsible for misrepresentations of biologically-based cause and effect, which they attribute to mutation-driven evolution, because they typically do not understand anything about epigenetics or the biophysical constraints on mutations.
JVK
not rated yet Jan 21, 2014
Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

http://www.freshp...8009.php

A potentially non-invasive treatment for Alzheimer's